Search | WHO COVID-19 Research Database

CCL-18, CHI3L1, Gal-3, Ang-2, IL-6 as biomarkers of lung damage in COVID-19

Ferrigno, I.; Bonacini, M.; Rossi, A.; Besutti, G.; Bonelli, E.; Tesse, D.; Colla, R.; Facciolongo, N.; Iori, M.; Teopompi, E.; Massari, M.; Mancuso, P.; Giorgi, R. P.; Ferrari, A. M.; Pattacini, P.; Zerbini, A.; Salvarani, C.; Croci, S..

European Journal of Immunology ; 52:46-47, 2022.

Article in English | Web of Science | ID: covidwho-2229975

Acute-phase reactants during tocilizumab therapy for severe COVID-19 pneumonia

Cassone, G.; Dolci, G.; Besutti, G.; Muratore, F.; Bajocchi, G.; Mancuso, P.; Catanoso, M. G.; Spaggiari, L.; Galli, E.; Palermo, A.; Pipitone, N.; Croci, S.; Massari, M.; Facciolongo, N.; Menzella, F.; Negri, E. A.; Zerbini, A.; Belloni, L.; Cimino, L.; Teopompi, E.; Sampaolesi, F.; Salsi, P.; Costantini, M.; Rossi, P. G.; Aldigeri, R.; et al..

Clinical and Experimental Rheumatology ; 38(6):1215-1222, 2020.

Article in English | GIM | ID: covidwho-1013702

ABSTRACT

Objectives: To identify predictors of clinical improvement and intubation/death in tocilizumab-treated severe COVID19, focusing on IL6 and CRP longitudinal monitoring.

ABSTRACT

SEND TO:

SELECTION OF CITATIONS

SEARCH DETAIL